I am the Robert K. Summy and Helen K. Summy Professor of Medicine and Director of the Lymphoma Program at Stanford University School of Medicine. I’m also the Associate Director of Translational Science for the Stanford Cancer Institute. For more than 25 years my research has focused on monoclonal antibodies and the study of malignant lymphoma, and my laboratory is currently using the tools of immunology and molecular biology to develop a better understanding of the initiation and progression of the malignant process. I was first to successfully treat cancer with a monoclonal antibody and went on to help develop rituximab (Rituxan^®) for the treatment of lymphomas. My group concentrates on using lymphocyte receptors as targets for new lymphoma therapies and we are currently conducting clinical trials of lymphoma vaccines. I have published over 300 articles in the fields of oncology and immunology.

In 1982, I shared the first Armand Hammer Award for Cancer Research, and was later awarded the Ciba-Geigy/Drew Award in Biomedical Research, the American Society of Clinical Oncology Karnofsky Award, the General Motors Charles Kettering Prize, the Key to the Cure Award by the Cure for Lymphoma Foundation, the Medal of Honor by the American Cancer Society, the Evelyn Hoffman Memorial Award by the Lymphoma Research Foundation of America, the 2004 Damashek Prize from the American Society of Hematology, and in 2009 I was elected to the National Academy of Sciences, and I won the King Faisal International Prize in Medicine.